Rectal cancer

This phase 2 trial is testing whether a short course of radiation followed by a powerful three-drug chemotherapy regimen (FOLFOXIRI) can completely eliminate tumors in people with locally advanced rectal cancer before they undergo surgery. The study enrolls adults aged 18 to 70 w…

This study looks at whether a combination of radiation and chemotherapy can cure low rectal cancer, allowing patients to avoid surgery. About 108 people with early-stage rectal tumors near the anus will receive this treatment. The main goal is to see if the cancer stays under con…

This early-phase trial tests a new treatment called NG-350A, a virus designed to stimulate the immune system inside tumors, combined with standard chemoradiotherapy for people with locally advanced rectal cancer. The study aims to see if this combination can improve the chance of…

This study tests whether giving a higher, targeted radiation dose to the main tumor and nearby lymph nodes can improve outcomes for people with locally advanced rectal cancer. About 128 adults whose cancer has not spread beyond the pelvis will receive either standard radiation or…

This study tests a device called ColoSeal ICD that is placed inside the colon after surgery to divert stool away from the surgical connection. The goal is to see if it is safe and feasible in 90 adults with rectal or rectosigmoid cancer. The device stays in place for about 10 day…

This study tests whether giving immunotherapy before surgery can help people with MSI/dMMR tumors. The goal is to shrink or eliminate the tumor before it is removed, potentially improving survival. The trial includes adults with localized, resectable cancers such as colorectal, g…

This phase 2 trial tests whether giving pembrolizumab, bevacizumab, and chemotherapy before surgery can improve outcomes for people with a common type of locally advanced rectal cancer. The cancer must be microsatellite stable, which typically does not respond well to immunothera…

This phase II trial compares a three-drug chemotherapy combination (FOLFIRINOX) against standard two-drug combos (FOLFOX or CAPOX) in 783 patients with locally advanced rectal cancer. The goal is to see if the stronger regimen leads to a complete disappearance of the tumor, poten…

This early-phase trial is testing a combination of chemotherapy (FOLFOX), an anti-angiogenic drug (bevacizumab), and two immunotherapies (botensilimab and balstilimab) in 20 patients with MSS metastatic colorectal cancer, a type that usually doesn't respond to immunotherapy. The …

This study tests whether giving two immunotherapy drugs (nivolumab and ipilimumab) along with a short course of radiation can completely eliminate advanced rectal cancer before surgery. About 31 adults with a specific genetic type (MSI-H/dMMR) of stage II or III rectal cancer wil…

This trial tests whether giving chemotherapy before or after standard chemoradiation improves outcomes for people with locally advanced rectal cancer. Participants receive either the standard approach (chemoradiation, surgery, then chemo) or a total neoadjuvant therapy approach w…

This phase 2 trial tests a new approach for people with locally advanced rectal cancer. Participants first receive a short course of radiation, followed by a combination of immunotherapy (sintilimab and IL-2) and chemotherapy (CAPOX). The goal is to see if this treatment can make…

This trial is testing whether a combination of chemotherapy drugs (liposomal irinotecan and capecitabine) plus radiation, given before surgery, can help people with locally advanced rectal cancer. The treatment plan is personalized based on a genetic marker (UGT1A1) that affects …

This trial is testing whether a more focused radiation field, combined with chemotherapy and an immunotherapy drug called camrelizumab, can improve outcomes for people with a certain type of locally advanced rectal cancer. The study will compare this new approach to a standard tr…

This study tests whether adding two immunotherapy drugs (atezolizumab and tiragolumab) after standard chemoradiation can help eliminate tumors in people with locally advanced rectal cancer. About 58 participants will receive either the drug combination or atezolizumab alone befor…

This early-phase trial is testing a new way of giving radiation therapy (ultra-fractionated, short course) along with standard chemotherapy for people with locally advanced rectal cancer. The goal is to see if this combination can shrink the tumor enough to avoid surgery. The stu…

This study tests a new drug, SX-682, alone and with the immunotherapy nivolumab, in people with a specific type of advanced colorectal cancer that has spread or cannot be removed. The cancer must have a RAS mutation and be microsatellite stable (MSS), which often makes it harder …

This study tests whether transplanting a person's own fecal bacteria into the bowel before ileostomy reversal can improve bowel and anal function after rectal cancer surgery. Participants receive four weekly enemas made from their own stool. The goal is to reduce symptoms like le…

This early-phase study tests whether giving healthy donor NK cells along with two medicines (vactosertib and IL-2) is safe and helps the cells stay active in people with advanced colorectal, stomach, esophageal, or blood cancers. The NK cells are meant to attack cancer, but the b…

This phase 1 trial tests a new method of delivering chemotherapy for people with cancers that have spread to the lining of the abdomen (peritoneal carcinomatosis) from gastrointestinal cancers like colorectal, stomach, or pancreatic cancer. The drug, nanoliposomal irinotecan (Oni…

This trial tests whether giving chemotherapy before or after radiation therapy works better for people with locally advanced rectal cancer that has a high risk of coming back. Participants receive the same drugs (capecitabine and oxaliplatin) but in a different order. The goal is…

This phase 2 trial is testing whether adding two drugs—a PCSK9 inhibitor and a PD-1 inhibitor—to standard chemoradiotherapy can help shrink tumors in patients with locally advanced rectal cancer that has a specific genetic profile (pMMR/MSS). The study involves 30 participants an…

This phase II trial tests whether adding the immunotherapy drug nivolumab to the standard two-drug regimen (encorafenib and cetuximab) works better at shrinking tumors in people with a specific type of advanced colorectal cancer (BRAF-mutant, microsatellite stable). About 86 part…

This study tests whether adding an immunotherapy drug (tislelizumab) to standard chemoradiation before surgery can improve outcomes for people with locally advanced rectal cancer. About 100 participants will receive the combination treatment, and researchers will measure how many…

This study tests whether adding two drugs—adebrelimab (an immunotherapy) and apatinib (a targeted therapy)—to standard chemoradiotherapy before surgery can improve outcomes for people with locally advanced or low-lying rectal cancer. The goal is to shrink the tumor enough to allo…

This Phase III trial tests whether a modified short-course radiation that spares nearby lymph nodes, combined with chemotherapy (CAPOX) and the immunotherapy drug tislelizumab, works better than standard radiation plus chemotherapy for people with a certain type of rectal cancer …

This phase II trial is testing whether adding an experimental immunotherapy drug (retlirafusp alfa) to short-course radiation and standard chemotherapy can completely eliminate locally advanced rectal cancer before surgery. The study plans to enroll 44 adults aged 18-70 with stag…

This phase 2 trial is testing whether adjusting treatment based on risk level can improve outcomes for people with HIV who have anal cancer. Low-risk patients receive standard chemotherapy and radiation, while high-risk patients also get the immunotherapy drug nivolumab after sta…

This study tests a combination of three drugs (cetuximab, LY3214996, and abemaciclib) in people with advanced colorectal cancer that has spread and no longer responds to standard therapy. The goal is to see if the combination can shrink tumors and improve survival. About 46 adult…

This study tests whether a combination of chemotherapy (FOLFOX) and a short course of radiation can eliminate advanced rectal cancer without needing surgery. 12 adults with locally advanced rectal cancer are being watched closely after treatment to see if the cancer fully respond…

This study looks at how well a new robotic surgical system works for removing colon or rectal tumors. About 60 adults who need surgery for benign or malignant colorectal conditions will take part. The goal is to see if the system is safe and can complete the surgery without switc…

This study tests four different tools—coaching, education, text messages, and health coaching—to help cancer survivors improve their diet, physical activity, and weight. About 350 adults who have completed treatment for several cancer types will use these tools for up to 48 weeks…

This early phase trial tests a biological product mix designed to train the immune system to recognize and kill CEA-positive rectal cancer cells. The study involves 20 participants with early-stage rectal cancer (Stage 0 to IIA) who have not yet developed symptoms or metastasis. …

This study tests whether a single immunotherapy drug, dostarlimab, can effectively treat people with a specific type of advanced rectal cancer (dMMR/MSI-H) that has not been treated before. About 154 participants will receive the drug and, if their cancer completely disappears, t…

This study tests whether eating 3-6 servings of fermented foods daily (like yogurt, kefir, and sauerkraut) can improve how well cancer treatments work in patients with locally advanced rectal cancer or non-small cell lung cancer. The 39 participants are randomly assigned to eithe…

This study tests a treatment plan to avoid major surgery for early-stage rectal cancer. Patients first receive chemotherapy, then a small surgery to remove the tumor, followed by radiation and more chemo. The goal is to see if this approach can cure the cancer while keeping the r…

This study tests whether combining two drugs (nivolumab and regorafenib) with short-course radiation can shrink tumors in people with stage II or III rectal cancer. About 72 participants will receive the drugs before and after radiation, followed by surgery or a watch-and-wait ap…

This study tests whether giving a single dose of radiation directly to the tumor area during surgery is feasible for people with advanced or recurrent rectal cancer. About 31 participants will be randomly assigned to receive standard surgery, surgery plus a standard radiation dos…

This phase 3 trial compares two treatment approaches for high-risk rectal cancer. The experimental group gets a short course of radiation (5 days) followed by several months of chemotherapy before surgery. The standard group receives longer chemoradiotherapy followed by surgery a…

This pilot study tests a new rectal applicator for delivering radiation therapy to elderly patients with inoperable rectal cancer. The treatment combines external beam radiation with three sessions of internal radiation (brachytherapy) using the new device. The study aims to see …

This study tests a new robotic surgery method for removing rectal tumors. The approach uses a single-port robot to improve flexibility and visibility during the operation. Researchers will study 20 patients with benign or early-stage rectal tumors to see if the procedure is safe …

This study tests a new surgical technique called transanal total mesorectal excision (taTME) for rectal cancer. Instead of operating from the abdomen, surgeons work from the anus upward, which may make it easier to remove the tumor completely. The trial includes 100 adults with e…

This phase 2 trial is testing a combination of two drugs, cabozantinib and nivolumab, in 48 people with advanced colorectal cancer that has not responded to standard treatments. The goal is to see if the combination can shrink or stabilize tumors. All participants have a type of …

This Phase 3 trial tests whether a short course of radiotherapy followed by the immunotherapy drug camrelizumab plus chemotherapy works better than standard long-term chemoradiation for locally advanced rectal cancer. About 230 patients will be randomly assigned to one of the two…

This study looks at whether closing the pelvic floor with stitches after removing rectal cancer can stop the bowel from getting blocked. About 516 people having keyhole surgery for mid-low rectal cancer will be randomly assigned to get the closure or not. The main goal is to see …

This study planned to test two drugs—regorafenib (a pill) and lorigerlimab (given by IV)—in people whose rectal cancer had come back or grown after standard treatment. The goal was to see if the combination was safe and effective. However, the trial was withdrawn before enrolling…

This Phase 2 trial tests a shorter course of radiation followed by FOLFOX chemotherapy before surgery for locally advanced rectal cancer. About 364 participants will be randomly assigned to either this new regimen or standard chemoradiation. The goal is to see if the shorter appr…

This study looks at standardizing the surgical process for patients with advanced or recurrent rectal cancer that has spread to nearby organs. The procedure, called pelvic exenteration, removes the tumor along with affected structures. The goal is to improve teamwork among surgeo…

This early-phase study tests an experimental oral drug (GSK4418959) in adults with advanced solid tumors that have specific genetic changes (dMMR or MSI-H). The drug works by blocking a protein (WRN) that these tumors need to survive. The study aims to see if the drug, alone or w…

This study compares two types of robotic surgery for high rectal and sigmoid colon cancer: one that removes the tumor through the anus (NOSES-IV) and the traditional method. The goal is to see which approach leads to fewer complications, less pain, and a shorter hospital stay. Ab…

This study tests a new approach for people with locally advanced rectal cancer that has a common genetic profile (MSS/pMMR). Instead of standard radiation before surgery, participants receive a combination of chemotherapy (mFOLFOX6) and an immunotherapy drug (PD-1 antibody). The …

This trial tests a modified stapling technique (MST) against the standard method in 450 adults having minimally invasive rectal cancer surgery. The goal is to see if MST reduces the chance of anastomotic leaks, a serious complication. Participants will be randomly assigned to one…

This study tests whether adding extra stitches around the surgical connection in laparoscopic low rectal cancer surgery can reduce the risk of dangerous leaks. About 300 adults with low rectal cancer will be assigned to either standard surgery or surgery with reinforced stitching…

This phase 2 trial tests whether adding the immunotherapy drug nivolumab (Opdivo) to standard chemoradiation and chemotherapy can improve outcomes for people with locally advanced rectal cancer. About 29 participants who have not had prior treatment will receive chemoradiation, t…

This study tests whether giving a powerful mix of chemotherapy and radiation before surgery can completely eliminate rectal cancer in more patients. About 38 adults with rectal cancer will receive the experimental treatment and be followed for up to 4 years. The goal is to see if…

This study tests whether a combination of chemotherapy and an immunotherapy drug (sintilimab) can effectively treat locally advanced rectal cancer without the need for radiation. The goal is to shrink or eliminate tumors before surgery, potentially preserving organ function. The …

This phase 2 trial tests a two-step approach for high-risk rectal cancer: first, a strong chemotherapy cocktail (FOLFOXIRI), followed by radiation combined with a chemo pill (capecitabine). The goal is to shrink tumors before surgery, making them easier to remove. The study invol…

This phase 2 trial tests whether adding a stronger chemotherapy regimen (FOLFOXIRI) before the usual chemoradiation and surgery can improve outcomes for people with high-risk locally advanced rectal cancer. About 72 participants will be randomly assigned to either standard treatm…

This study looks at whether a special drink made with easily digested protein and MCT oil can help improve malnutrition in cancer patients who are having radiotherapy. The study will follow 132 adults with head and neck, lung, rectal, or esophageal cancer for 12 weeks. Researcher…

This study tests a new platform called xDRIVE that combines drug sensitivity testing and AI to predict which treatments will work best for people with advanced colorectal cancer. The platform will not provide treatment itself but will give doctors a recommendation. The goal is to…

This early-phase trial tests a special PET scan that uses a radioactive tracer (64Cu-M5A) to highlight rectal cancer cells. The goal is to see if this scan can show tumor extent and response more accurately than standard imaging before and after chemotherapy and radiation. About …

This study tests a new radioactive tracer called 18F-alphavbeta6-binding-peptide to see if it can safely and clearly show cancers in the breast, colon, lung, or pancreas. About 27 adults with these cancers will get the tracer and have a PET scan. The goal is to find out if this m…

This study tests a special PET scan that uses a radioactive antibody (64Cu-M5A) to find cancers that produce a protein called CEA. The goal is to see if this scan can detect tumors that standard methods might miss. About 20 adults with CEA-positive cancers (such as breast, colon,…

This study tests whether taking two drugs, eflornithine and sulindac, together can lower the chance of new high-risk growths or a second colon cancer in people who have already had stage 0 to III colon or rectal cancer. About 350 participants who are cancer-free after surgery wil…

This early-phase study tests an oral drug called ropidoxuridine (IPdR) in people with advanced gastrointestinal cancers that cannot be cured. The goal is to find the safest dose and see if it can make radiation therapy more effective at shrinking tumors. Nineteen participants wit…

This study tests a program that combines pelvic floor physical therapy with coping skills training to help women who have had pelvic radiation for cancer. The goal is to improve sexual function and quality of life. The study involves 12 cancer survivors and focuses on whether the…

This phase II trial tests whether time-restricted eating (intermittent fasting) can reduce side effects from radiation or chemoradiation in people with prostate, cervical, or rectal cancers. About 49 participants will either follow a time-restricted eating plan or receive standar…

This study tests a personalized self-management program to help cancer survivors on immune checkpoint inhibitors better handle side effects and reduce anxiety or depression. About 400 adults with breast, colon, lung, skin, or rectal cancer who recently started immunotherapy will …

This study tests whether using telemedicine and remote monitoring can help people with advanced digestive cancers manage chemotherapy side effects at home, reducing the need for emergency room visits and hospital stays. About 750 patients and their caregivers will receive enhance…

This study tests whether transanal irrigation (using water to flush the bowel) can improve quality of life and reduce bowel symptoms in 66 rectal cancer survivors who have low anterior resection syndrome (LARS). Participants learn the technique through an online platform with vir…

This study tests whether adding a single, non-invasive biofeedback session to home Kegel exercises can improve bowel control, reduce emotional distress, and enhance quality of life in people who have had rectal cancer surgery. About 66 participants will be randomly assigned to ei…

This study tests a program that lets cancer patients receive care at home while undergoing chemotherapy or radiation. It includes remote monitoring and home visits to reduce the need for hospital stays or emergency room visits. The goal is to see if this approach improves quality…

This study tests whether a 6-week online program based on Acceptance and Commitment Therapy (ACT) can help cancer survivors who have finished treatment feel less anxious and depressed. 32 survivors of breast, colon, or rectal cancer will be randomly assigned to either the online …

This study tests whether using a FitBit and a mobile app can help people recover at home after surgery for stomach, liver, colon, or other GI cancers. About 107 patients will either use the devices plus standard care, or standard care alone. The app tracks activity and symptoms, …

This study tests whether adding chlorophyllin, a natural plant extract, to standard chemoradiation can reduce side effects like diarrhea, bladder irritation, and low blood counts in people with locally advanced rectal cancer. About 76 adults will receive either chlorophyllin or a…

This study looks at tiny pieces of cancer cells or DNA floating in the blood of people with rectal cancer. Researchers want to see if these markers can help predict how the tumor responds to standard treatment. About 341 participants, including healthy volunteers, will provide bl…

This study follows 116 people with recurrent rectal cancer to understand how their treatment affects their quality of life and well-being. Participants fill out questionnaires every 3 months about their symptoms, daily activities, and overall health. The goal is to learn what mat…

This study follows 565 people with stage I-III colon or rectal cancer to understand how treatment affects their finances and quality of life. Participants complete surveys about costs and financial well-being over 12 months. The goal is to help doctors better support patients fac…

This pilot study is testing whether regular MRI scans and blood tests can accurately track how rectal cancer responds to pre-surgery treatment. The goal is to develop a way to predict complete remission without needing surgery. Forty adults with locally advanced rectal cancer wil…

This study planned to look back at MRI scans of people with rectal cancer to see if the images could predict how aggressive the cancer is and how well it responds to treatment. The goal was to create a computer model to help doctors make better decisions. However, the study was w…

This study tests whether AI-generated messages can change how cancer survivors think about alcohol and cancer risk. About 850 adults who have had certain cancers and currently drink alcohol will view different messages. Researchers will measure changes in their beliefs about canc…

This study tests whether a simple blood test that looks for tumor DNA can detect colorectal cancer coming back earlier than standard CT scans. About 359 people who had surgery for stage II or III colorectal cancer will be randomly assigned to either the blood test plus frequent P…

This study involves 320 adults with advanced rectal cancer who received standard chemoradiotherapy and surgery. Researchers are building a computer model that uses MRI scans and patient data to predict whether the cancer has completely disappeared after treatment. The goal is to …

This study planned to test if a 7-week program of aerobic and resistance exercise is feasible for people with locally advanced rectal cancer undergoing short-course radiotherapy. It aimed to recruit 30 patients and track how many joined, attended sessions, and stayed in the study…

This study looks at 266 adults with advanced rectal cancer who had radiation therapy followed by surgery. It compares standard chemoradiotherapy or short-course radiotherapy with a newer approach called total neoadjuvant treatment (TNT). The goal is to see which method leads to f…

This study searches for new gene changes (mutations) that appear in cancer patients but not in their healthy parents. By comparing DNA from 1,275 people with certain cancers and their families, researchers hope to find genetic clues that increase cancer risk. The goal is to bette…

This study looks at how moderate aerobic exercise (like brisk walking) might help prevent colorectal cancer from coming back. Researchers will measure changes in inflammation and other blood markers in 60 people who have finished cancer treatment. Participants either walk on a tr…